728x90 반응형 SMALL takeda1 Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor With Marketing Authorization Submissions in the U.S., European Union and Japan Planned in 2023, Fruquintinib Offers a Potential New Treatment Option for Patients with Refractory Metastatic Colorectal Cancer Licensing Agreement for Fruquintinib Strengthens Takeda’s Growing Oncology Portfolio Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with .. 2023. 1. 24. 이전 1 다음 728x90 반응형 LIST